title: New Merck and Vertex drugs raise standard of care in hepatitis C.
authors: Cormac
authors: C
authors: Sheridan
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D004345:Drug Industry / Q000639:trends*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011787:Quality of Health Care / Q000639:trends*; D014481:United States
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline